A retreat that treats your medication list like a minor administrative detail is showing you its safety culture before you arrive. This medications contraindicated with ayahuasca guide is not a substitute for individualized medical care. It is a consumer-protection tool for recognizing when a retreat needs to slow down, ask better questions, and involve a qualified prescribing clinician rather than pushing a sale.
Ayahuasca is commonly understood to combine plant compounds that include reversible monoamine oxidase inhibitors, often called MAOIs, with a DMT-containing plant. That pharmacology is why medication screening is not optional. Interactions can be serious, and a retreat’s intake form cannot replace a review by the clinician who knows your prescriptions, medical history, and current mental health care. (ICEERS; Johns Hopkins Center for Psychedelic and Consciousness Research)
> Medical disclaimer: This article is general education, not medical advice, diagnosis, or a medication plan. Do not start, stop, taper, skip, or change any prescribed medication to attend an ayahuasca retreat. Speak with the licensed clinician who prescribes your medication and disclose all prescription drugs, over-the-counter products, supplements, and substances to any prospective retreat.
Table of contents
- Why ayahuasca medication screening matters
- Medication categories that require clinical review
- Why washout charts are not a safety plan
- Questions a responsible retreat should ask
- Red flags that should end the conversation
- Frequently asked questions
Why ayahuasca medication screening matters
The central risk is not whether a medicine appears on a generic internet checklist. It is the interaction between a person’s complete medication profile, underlying health conditions, recent medication changes, other substances, and the pharmacological effects of ayahuasca. Serotonin toxicity, blood-pressure complications, altered seizure risk, and psychiatric destabilization are among the concerns that demand qualified assessment in psychedelic settings. (PubMed; ICEERS; MAPS)
That means broad claims such as “natural medicines are safe” or “our shaman knows what you need” are not reassuring. They are evasive. A responsible operator should explain that they do not make prescribing decisions, should collect information early enough for a participant to seek clinical guidance, and should be willing to decline someone when safety information is incomplete.
Medications contraindicated with ayahuasca: categories to review
The word “contraindicated” is often used loosely online. In practice, a qualified clinician must determine whether a particular medication, dose history, indication, and timing create an unacceptable risk. The categories below are not a complete list, and they are not permission to self-manage a medication change.
| Medication or substance category | Why it may matter with ayahuasca | What a safer screening process looks like | |—|—|—| | Antidepressants that affect serotonin, including SSRIs, SNRIs, TCAs, and some atypical antidepressants | Combining serotonergic medicines with MAOI-containing preparations may raise concern for serotonin toxicity and other adverse effects. (ICEERS; PubMed) | The retreat asks for the exact medicine and prescriber contact process, then requires independent clinical review. | | Prescription MAOIs and other medicines with MAOI activity | Overlapping MAOI effects can create significant interaction concerns and requires specialist evaluation. (PubMed; ICEERS) | The operator does not offer a generic timeline or make a clearance decision. | | Stimulants and certain ADHD medications | Stimulant effects and cardiovascular considerations may complicate risk assessment, particularly where blood pressure or heart history is relevant. (PubMed; Johns Hopkins Center for Psychedelic and Consciousness Research) | Screening includes cardiovascular history, current use, and clinician input rather than a blanket promise. | | Opioids, cough medicines, and pain medicines with serotonergic activity, such as tramadol or dextromethorphan products | Some products in these categories can affect serotonin signaling or have other interaction concerns. Combination products make self-screening especially unreliable. (PubMed; ICEERS) | The retreat requests brand and generic names, not just “pain medicine” or “cold medicine.” | | Antipsychotics, mood stabilizers, benzodiazepines, and seizure medications | These medicines can signal psychiatric or neurological histories that need individualized assessment. Abrupt changes can also carry their own risks. (MAPS; Johns Hopkins Center for Psychedelic and Consciousness Research) | A retreat distinguishes between medication screening and mental-health readiness screening, and does not tell guests to discontinue treatment. |
Other products matter too. Migraine medicines, sleep aids, allergy and cold products, weight-loss drugs, herbal preparations, and recreational substances can all complicate a review depending on their active ingredients and a person’s health profile. “It is only over the counter” is not a reliable safety category. (ICEERS; PubMed)
The hidden problem: incomplete disclosure
People often forget occasional medicines because they do not think of them as medications. A cough syrup used last week, a rescue migraine drug, a sleep aid, a pre-workout supplement, or a cannabis product may be relevant. The same goes for medicines obtained in another country under a different brand name.
A competent intake process gives participants space to disclose without shame. It asks about prescriptions, nonprescription products, supplements, and recent substance use separately. It also explains who reviews that information and what happens if the answer raises a concern. Vague promises of confidentiality are not enough when nobody can identify the actual reviewer.
Why washout charts are not a safety plan
Retreat marketing sometimes presents a simple “stop X for Y days” chart as if it settles the issue. It does not. Medication discontinuation can cause withdrawal effects, symptom recurrence, or other complications, while individual metabolism, dose history, co-prescribed medicines, and the underlying reason for treatment all matter. (PubMed; MAPS)
No retreat facilitator, online forum, or generic chart should direct you to stop psychiatric medication. A legitimate center should say clearly that medication decisions belong with the prescribing clinician. If an operator pressures you to quit treatment to secure a reservation, they are placing conversion ahead of care.
This is also where the business model matters. A platform that profits from bookings has a built-in reason to keep a prospective guest moving toward checkout. Best Retreats takes the opposite position: no bookings, no bias, just raw, honest research. Medication screening should be treated as a possible stop sign, not an obstacle to be managed away.
Questions a responsible retreat should ask
Before you pay a deposit, ask how the center handles medication and medical screening. You are not looking for mystical certainty. You are looking for accountable systems.
A credible answer identifies who reviews intake information, whether that person has relevant clinical qualifications, when screening happens, and how the center handles a participant who is not cleared. It should also explain emergency planning, access to local medical care, and whether facilitators know how to respond to a medical escalation. Psychedelic settings require clear protocols, not just assurances that participants will be watched. (MAPS; ICEERS)
Ask whether the retreat reviews every active medication by generic name, including nonprescription products and supplements. Ask whether it requires stable, honest disclosure before travel. Then ask the uncomfortable question: “Will you tell me not to come if you cannot assess my risk?” A safety-first operator can answer yes.
Red flags that should end the conversation
Walk away from a retreat that says medication interactions are “all fear-based,” tells you that plant medicine overrides pharmaceuticals, or offers individualized tapering instructions without your prescriber. Those are not alternative perspectives. They are signs that the center may be practicing beyond its competence.
Other concerns include a one-line health form, screening only after a nonrefundable payment, no explanation of emergency procedures, or staff who cannot say who reviews contraindications. A retreat may not be able to disclose every operational detail, but it should be able to describe its safety process without becoming defensive.
If you experience pressure, misleading screening, withheld safety information, facilitator misconduct, or an incident at a retreat, document what happened while details are fresh and submit a report through the Best Retreats retreat incident reporting page. Consumer reports help expose patterns that polished testimonials routinely miss.
Frequently asked questions
Can I attend an ayahuasca retreat while taking antidepressants?
Do not rely on a retreat’s answer alone. Some antidepressants may present meaningful interaction concerns with MAOI-containing ayahuasca preparations, and the correct next step is an individualized conversation with your prescribing clinician. Do not change medication on your own to make travel possible. (ICEERS; PubMed)
Are supplements relevant to ayahuasca screening?
Yes. Supplements and herbal products can have active effects, may contain multiple ingredients, and are frequently overlooked during intake. Share the exact product name and ingredient list with your clinician and the retreat’s screening team. (ICEERS; PubMed)
What if a retreat says it has never had a problem?
That statement is not evidence of a competent safety system. It may reflect poor recordkeeping, underreporting, narrow definitions of harm, or a marketing response. Ask for concrete policies, reviewer qualifications, emergency procedures, and how the center handles disclosures that make participation unsafe.
A retreat worthy of your trust will never make you choose between honest health disclosure and belonging. If the screening process feels rushed, secretive, or sales-driven, treat that discomfort as useful information and step back before committing.